Hormone therapy

How does hormone therapy work?

Hormone therapy works by either stopping your body from making testosterone, or by stopping testosterone from reaching the cancer cells.

Prostate cancer cells usually need testosterone to grow. Testosterone is a hormone that controls how the prostate grows and develops. It also controls other male characteristics, such as muscle strength, erections, and the size and function of the penis and testicles.

Testosterone doesn’t usually cause problems but, if you have prostate cancer, it can make the cancer cells grow faster. If testosterone is taken away, the cancer will usually shrink, even if it has spread to other parts of your body.

Hormone therapy on its own won’t cure your prostate cancer. If you have hormone therapy on its own, the treatment will aim to control your cancer and delay or manage any symptoms. Hormone therapy can also be used with other treatments, such as radiotherapy, to make the treatment more effective.

Download or order Hormone therapy fact sheet

Watch our video about hormone therapy to find out more:

Who can have hormone therapy?

Hormone therapy is an option for many people with prostate cancer, but it’s used in different ways depending on whether your cancer has spread.

Localised (early) prostate cancer

If your cancer hasn’t spread outside the prostate (localised prostate cancer), you might have hormone therapy alongside your main treatment. Hormone therapy can shrink the prostate and any cancer inside it, which makes the cancer easier to treat. It can also make your main treatment more effective. You might have hormone therapy:

for six months before, during or after external beam radiotherapy
for up to three years after external beam radiotherapy, if there is a risk of your cancer spreading outside the prostate.

Hormone therapy is not usually given to men having surgery to remove their prostate (radical prostatectomy), HIFU or permanent seed brachytherapy.

Read more about localised prostate cancer.

Locally advanced prostate cancer

If your cancer has spread to the area just outside the prostate (locally advanced prostate cancer), you may have hormone therapy before, during and after radiotherapy. Hormone therapy can help shrink the prostate and any cancer that has spread, and make the treatment more effective.

You may be offered hormone therapy for up to six months before radiotherapy. And you may continue to have hormone therapy during and after your radiotherapy, for up to three years.

Some men might have hormone therapy on its own if radiotherapy or surgery aren’t suitable for them.

Read more about locally advanced prostate cancer.

Advanced (metastatic) prostate cancer

Hormone therapy will be a life-long treatment for most men with prostate cancer that has spread to other parts of the body (advanced or metastatic prostate cancer).

Hormone therapy shrinks the cancer and slows down its growth, wherever it has spread to in the body. It can’t cure the cancer, but it can keep it under control, often for years. It can also help manage symptoms of advanced cancer, such as bone pain.

How long it will control the cancer for varies from person to person. It may depend on how aggressive your cancer is and how far it has spread. It’s difficult for doctors to know exactly how long it will keep your cancer under control. Speak to your doctor or nurse about your own situation.

Read more about advanced prostate cancer.

Prostate cancer that has come back after treatment (recurrent prostate cancer)

If your cancer has come back after treatment for localised or locally advanced prostate cancer, hormone therapy will be one of the treatments available to you.

Read more about recurrent prostate cancer.

Unsure about your diagnosis and treatment options?

If you have any questions about your diagnosis at any time, ask your doctor or nurse. They can explain your test results and your treatment options. Make sure you have all the information you need. Read more about how prostate cancer is diagnosed.

It is normal to feel overwhelmed. You may not be able to understand all the information you are given at first. Take your time to process the information given to you and ask any questions about anything you don’t understand. Our Specialist Nurses are also here to support you and can help with any questions you have.

What types of hormone therapy are there?

There are three main ways to have hormone therapy for prostate cancer. These are:

injections or implants
tablets
surgery to remove the testicles (orchidectomy).

The type of hormone therapy you have will depend on whether your cancer has spread, any other treatments you’re having, and your own personal choice. You may have more than one type of hormone therapy at the same time.

Injections or implants

These stop your body from making testosterone. They work by blocking the message from the brain that tells your testicles to make testosterone. Injections or implants are as good at controlling prostate cancer as surgery to remove the testicles.

Ask your doctor or nurse whether you will have injections or implants. They are both given using a needle.

Injections use a needle to inject a small amount of liquid under the skin or into muscle. They may be given in your arm, abdomen (stomach area), thigh or bottom (buttock), depending on the type you’re having.

Implants may be given as a small pellet that is placed under the skin in the abdomen and slowly releases the drug.

How often will I have injections?

You will have the injections or implants at your GP surgery or local hospital. How often you have them will vary, depending on the type you are having. Some men have an injection or implant once a month, while others have them every three or six months.

LHRH agonists

LHRH agonists (luteinizing hormone-releasing hormone agonists) are the most common type of injection or implant. There are several available that all work in the same way, including:

goserelin (Zoladex®)
leuprorelin acetate (Prostap® or Lutrate®)
triptorelin (Decapeptyl® or Gonapeptyl Depot®)
buserelin acetate (Suprefact®).

LHRH agonists cause the body to produce more testosterone for a short time after the first injection. This usually happens about two or three days after you have the first injection.

This temporary surge in testosterone could cause the cancer to grow more quickly for a short time, which might make any symptoms you have worse for about a week – this is known as a flare.

If you’re having an LHRH agonist, you’ll be given a short course of anti-androgen tablets as well. This should stop any problems caused by this surge of testosterone.

You’ll usually start taking the anti-androgen tablets before your first injection or implant and keep taking them for a few weeks.

GnRH antagonists

GnRH antagonists (gonadotrophin-releasing hormone antagonists) are used less often than LHRH agonists. You may also hear them called GnRH blockers.

Degarelix (Firmagon®)

Degarelix can be used as a first treatment for advanced prostate cancer. When you first start degarelix, you will have two injections on the same day – one on each side of your abdomen (stomach area). You will then have one injection each month, or some men switch to an LHRH agonist.

Unlike LHRH agonists, degarelix doesn’t cause a surge in testosterone with the first treatment, so you won’t need to take anti-androgen tablets. Instead your testosterone levels will start to drop straight away, usually on the first day of having treatment.

If have degarelix, the skin around the area where you have the injections may feel red, hard, swollen and sore. This usually settles down after a few days. Mild pain-relieving medicines, such as paracetamol, or using a cool pack on the area can help.

Keeping track of your injections

If you’re having injections, it’s a good idea to record all the dates so that you don’t miss an appointment. There’s space to record details in our booklet, Living with hormone therapy: A guide for men with prostate cancer.

If your injection is a few days late, it shouldn’t be a problem. But if your injection is late by a couple of weeks or more, your body may start to produce more testosterone, which may cause the cancer to start growing again.

If you think you’ve missed an injection, tell your doctor or nurse as soon as possible.

Tablets

Anti-androgens

Anti-androgen tablets stop testosterone from reaching the cancer cells. They can be used:

on their own
before having injections or implants
together with injections or implants
after surgery to remove the testicles (orchidectomy).

There are different types of anti-androgen tablets, including:

bicalutamide (Casodex®)
cyproterone acetate (Cyprostat®)
flutamide (Drogenil®).

Ask your doctor how long you’ll need to take anti-androgens for, and whether you’re having them with another treatment or on their own.

Anti-androgens taken on their own are less likely to cause sexual problems and bone thinning than other types of hormone therapy. But they may be more likely to cause breast swelling and tenderness. You also have a higher risk of liver problems if you take anti-androgens. Before you start taking them, you may have some tests to check your liver. Or if you’ve had liver problems before, anti-androgen tablets might not be suitable for you.

If your cancer is advanced, anti-androgens will be less effective than other types of hormone therapy. So if you have advanced cancer, your doctor will usually recommend an LHRH agonist.

GnRH antagonists - Relugolix (Orgovyx®)

Relugolix is a new type of hormone therapy used to treat some men with prostate cancer. Unlike other GnRH antagonists such as degarelix, relugolix is given as a tablet. Find out more about relugolix.

Androgen receptor pathway inhibitors (ARPI)

There are newer types of hormone therapy that can be used to treat some men with prostate cancer. You may hear them called new or second-generation hormone therapy. They may be used in combination with first line hormone therapy treatment, or when your prostate cancer has stopped responding other types of hormone therapy. They include the following:

Abiraterone (Zytiga®) tablets are most commonly given to men with advanced prostate cancer that’s stopped responding to standard hormone therapy. But some hospitals now offer abiraterone as a first treatment for advanced prostate cancer. Find out more about abiraterone.
Enzalutamide (Xtandi®) tablets may be offered to men with advanced prostate cancer as a first treatment in combination with other treatments, or if your cancer has stopped responding to other types of hormone therapy. Find out more about enzalutamide.
Darolutamide (Nubeqa®) tablets may be used to treat some men with prostate cancer. It won’t cure your prostate cancer, but it can help keep it under control. It has also been shown to give some men longer before their cancer spreads to other parts of the body (advanced prostate cancer). Find out more about darolutamide.
Apalutamide (Erleada®) tablets may be offered to some men with localised prostate cancer or locally advanced prostate cancer that has stopped responding to other types of hormone therapy. It has also been shown to give some men longer before their cancer spreads to other parts of the body (advanced prostate cancer). Find out more about apalutamide.

Surgery to remove the testicles (orchidectomy)

You may be offered an operation to remove the testicles, or the parts of the testicles that make testosterone. This is called an orchidectomy (or orchiectomy). It’s not used as often as other types of hormone therapy.

Surgery is very effective at reducing testosterone levels, which should drop to their lowest level very quickly – usually in less than 12 hours. It also means that you won’t need to have regular injections, so there’s no risk that you’ll miss an injection.

Surgery can’t be reversed, so it’s usually only offered to men who need long-term hormone therapy. If you’re thinking about having surgery, your doctor may suggest trying injections or implants for a while first. This will give you and your doctor a chance to see how you deal with the side effects of low testosterone.

Short-term side effects of an orchidectomy include swelling and bruising of the scrotum (the skin containing the testicles).

Some men find the thought of having an orchidectomy upsetting and worry about how they’ll feel once their testicles are removed. Speak to your doctor if you have any concerns. If you don’t want an orchidectomy, you can usually have a different type of hormone therapy instead.

What are the advantages and disadvantages of hormone therapy?

What may be important to one person might be less important to someone else. So speak to your doctor or nurse about your own situation.

Advantages

It’s an effective way to control prostate cancer, even if it has spread to other parts of your body.
It can be used alongside other treatments to make them more effective.
It can help to reduce some of the symptoms of advanced prostate cancer, such as urinary symptoms and bone pain.

Disadvantages

It can cause side effects that might have a big impact on your daily life.
It can’t cure your cancer when it’s used by itself, but it can help to keep the cancer under control, sometimes for many years.

What are the side effects of hormone therapy?

Like all treatments, hormone therapy can cause side effects. It’s important to remember hormone therapy affects men in different ways, and you may not get all of the possible side effects. Some men only get a few side effects or don’t get any at all.

We describe the most common side effects of hormone therapy below. If you have any questions about side effect, speak to your doctor or nurse, or call one of our Specialist Nurses.

Hot flushes

Hot flushes are a common side effect of hormone therapy. They give you a sudden feeling of warmth in your body. You might feel very hot in your face, neck, chest or back. They can vary from a few seconds of feeling very hot to a few hours of sweating, which can be uncomfortable. Read more about hot flushes, including ways to help manage them.

Extreme tiredness (fatigue)

Hormone therapy can make you feel extremely tired, which could affect your everyday life. Fatigue can come on quite suddenly and can make it difficult to carry out your daily activities. It can also affect how you feel emotionally, and you may feel down. But there are things that can help manage your fatigue. Read more about fatigue and prostate cancer, and ways to manage it.

Changes to your sex life

Hormone therapy can cause the following changes to your sex life:

less desire for sex (low libido)
problems getting or keeping an erection (erectile dysfunction)
producing less semen and having less intense orgasms
changes to the size of your penis and the size or shape of your testicles.

There are treatments and ways to manage changes to your sex life. Read more about prostate cancer and your sex life.

Weight gain

Some people put on weight while they’re on hormone therapy, particularly around the waist. Some men find this hard to deal with, especially if they’ve never had problems with their weight in the past. Keeping active and eating a healthy diet can help. Read more about diet and physical activity.

Strength and muscle loss

Testosterone plays an important part in the physical make up of men’s bodies. Hormone therapy can cause you to lose some muscle tissue. This can change the way your body looks and how physically strong you feel. Read more about strength and muscles loss.

Memory and concentration

If you’re having hormone therapy you may find it difficult to concentrate or focus on certain tasks. Or you might struggle to remember things as well as you used to. Read more about changes to you memory and concentration.

Breast swelling or tenderness

Hormone therapy may cause swelling (gynaecomastia) or tenderness in the chest area. The amount of swelling can vary from a small amount to noticeable breasts. Tenderness can affect one or both sides of the chest and can range from mild sensitivity to long-lasting pain. Read more about breast swelling or tenderness.

Loss of body hair

Some men lose their body hair while they are on hormone therapy. This can happen anywhere on your body, including your face, chest and pubic area. The hair should grow back if you stop hormone therapy.

Bone thinning

Testosterone helps to keep bones strong. Long-term hormone therapy can make your bones weaker and cause a condition called osteoporosis. This means you may be more likely to have broken bones (fractures). Read more about bone thinning.

Risk of other health problems

Hormone therapy may slightly increase your chance of developing other health problems, including:

heart disease
stroke
type-2 diabetes
blood clots.

Before you start hormone therapy, tell your doctor if you’ve ever had any of the problems listed above, or if you’re taking medicines to treat another health problem, such as high blood pressure (hypertension) or high levels of cholesterol (hypercholesterolaemia). Read more about risk of health problems.

Changes to your mood

Hormone therapy can affect your mood. You may feel more emotional than usual or just ‘different’ to how you felt before. Some men find that they cry a lot. You may also get mood swings, such as feeling tearful then angry.

Some men experience low moods, anxiety or depression. This could be caused by the hormone therapy itself, or by dealing with your prostate cancer diagnosis. It could also be due to the impact that treatment is having on your life. Read more about mood changes, including what can help.

How long will side effects last?

Some men find their side effects improve or get easier to manage the longer they’re on hormone therapy. But if side effects don’t improve, there are usually ways to manage them.

Side effects will usually last for as long as you’re on hormone therapy. If you stop using it, the side effects should improve as your testosterone levels start to rise again. Your side effects won’t stop straight away – it may take several months or years. For some men, the side effects may never go away completely.

Find out more about side effects of hormone therapy and how you can manage them.

Specialist Nurse support for life on hormone therapy

Many men find it difficult to deal with the emotional impact of side effects. It’s important to remember you are not alone and there is support available. Our specialist nurses run free ‘Life on ADT' online classes to help support men, answer questions and connect men with others going through the same thing.

Find out more and sign up here.

How will I know if my treatment is working?

You will have regular appointments to check how well your treatment is working and monitor any side effects. These will involve regular prostate specific antigen (PSA) blood tests to measure the amount of PSA in your blood. PSA is a protein produced by cells in your prostate and also by prostate cancer cells, even if they have spread to other parts of your body. The PSA test is a good way to check how well your treatment is working.

How your treatment is monitored will depend on whether you’re having hormone therapy as part of treatment that aims to cure your prostate cancer, or having life-long hormone therapy to keep advanced prostate cancer under control.

You can contact your nurse at the hospital, or our Specialist Nurses, between appointments if you have any side effects or symptoms that you’d like to talk about.

What happens next?

If you’re having treatment that aims to cure your prostate cancer

If your PSA level falls and stays low, this usually suggests your treatment is working. How quickly your PSA level falls, and how low, will depend on the type of treatment you’ve had and will be different for everyone. Read more about follow-up after prostate cancer treatment.

Speak to your doctor or nurse about how long you will have hormone therapy for. After you stop having hormone therapy, you’ll continue to have regular follow-up appointments, including PSA tests.

If you’ve had radiotherapy, your PSA level may rise a little when you stop hormone therapy. If it continues to rise, this could mean that your prostate cancer has come back.

Your doctor might suggest that you have some scans to see if anything has changed. They will then be able to talk to you about further treatments, if you need them. Read more about recurrent prostate cancer.

If you’re having life-long hormone therapy for advanced prostate cancer

If you have advanced prostate cancer, it’s likely that you’ll have hormone therapy as a life-long treatment.

As well as regular PSA tests, your doctor will check for any changes in symptoms such as pain or weight loss. You may also have regular scans to keep an eye on your cancer.

If your PSA level starts to rise or your scans show changes, this may be the first sign that your hormone therapy is no longer working so well. If this happens, your doctor will talk to you about other possible treatment options.

You may be offered other types of hormone therapy, a combination of different hormone therapy drugs, or a different type of treatment.

Intermittent hormone therapy

If you’re on life-long hormone therapy and are finding the side effects difficult to manage, you might be able to have intermittent hormone therapy. This is where you stop hormone therapy when your PSA level is low and steady, and start it again if your symptoms get worse or your PSA rises to around 10 or higher.

Some of the side effects, such as hot flushes and sexual problems, may improve while you’re not having treatment. But it can take several months for side effects to improve, and some men never notice any improvement. Read more about living with hormone therapy.

Questions to ask your doctor or nurse

What is the aim of treatment?
What type of hormone therapy are you recommending for me and why?
How often will I have my injections or implants?
How will my treatment be monitored?
How long will it be before we know if the hormone therapy is working?
What are the possible side effects, and how long will they last?
What will happen if I decide to stop my treatment?
Are there any clinical trials that I could take part in?

References

Updated: November 2024 | Due for Review: November 2027

List of references

Abrahamsson PA. Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots. Asian J Urol. 2017 Oct;4(4):208–22.
Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013 Apr;111(4):543–8.
Andela CD, Matte R, Jazet IM, Zonneveld WC, Schoones JW, Meinders AE. Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review. Int J Urol. 2021;28(8):786–98.
Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review. Urol Int. 2018;100(3):251–62.
Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Mar 1;33(7):716–22.
Casey RG, Corcoran NM, Larry Goldenberg S. Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl. 2012 Mar;14(2):226–31.
Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115(2):256–66.
Cornford P, van den Bergh RCN, Briers E, De Santis M, Gillessen S, Henry AM, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. European Association of Urology; 2024.
Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139(12):2698–704.
Crouzet S, Chapelon JY, Rouvière O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, et al. Whole-gland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients. Eur Urol. 2014 May;65(5):907–14.
Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, et al. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023 Dec 1;84(6):547–60.
Dong Z, Wang H, Xu M, Li Y, Hou M, Wei Y, et al. Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: a meta-analysis. Aging Male. 2015 Dec;18(4):233–7.
Edmunds K, Tuffaha H, Galvão DA, Scuffham P, Newton RU. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Support Care Cancer. 2020 May 1;28(5):2079–93.
Edmunds K, Tuffaha H, Scuffham P, Galvão DA, Newton RU. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review. Support Care Cancer. 2020 Dec;28(12):5661–71.
Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW. Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life: Improving Life on ADT. J Sex Med. 2010 Sep;7(9):2996–3010.
Fang C, Wu CL, Liu SS, Ge L, Bai JL. Efficacy, safety, and dose comparison of degarelix for the treatment of prostate cancer: A systematic review and meta-analysis. World J Meta-Anal. 2016 Jun 26;4(3):69–76.
Gagliano-Jucá T, Travison TG, Nguyen PL, Kantoff PW, Taplin ME, Kibel AS, et al. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2018 Feb 1;55(2):307-317.e1.
Gardner JR, Livingston PM, Fraser SF. Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review. J Clin Oncol. 2014 Feb 1;32(4):335–46.
Geerkens MJM, Pouwels NSA, Beerlage HP. The effectiveness of lifestyle interventions to reduce side effects of androgen deprivation therapy for men with prostate cancer: a systematic review. Qual Life Res. 2020;29(4):843–65.
Gunlusoy B, Ceylan Y, Koskderelioglu A, Gedizlioglu M, Degirmenci T, Ortan P, et al. Cognitive Effects of Androgen Deprivation Therapy in Men With Advanced Prostate Cancer. Urology. 2017 May 1;103:167–72.
Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018 Jul 9;1.
Hechtman LM. Clinical Naturopathic Medicine [Internet]. Harcourt Publishers Group (Australia); 2014 [cited 2015 Jul 21]. 1610 p. Available from: http://www.bookdepository.com/Clinical-Naturopathic-Medicine-Leah-Hechtman/9780729541923
Henson CC, Burden S, Davidson SE, Lal S. Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy. Cochrane Database Syst Rev [Internet]. 2013 [cited 2014 Nov 18];(11). Available from: http://doi.wiley.com/10.1002/14651858.CD009896.pub2
Hicks BM, Klil-Drori AJ, Yin H, Campeau L, Azoulay L. Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer: Epidemiology. 2017 Sep;28(5):712–8.
Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61(2):32–8.
Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, et al. Testosterone and Prostate Cancer: Revisiting Old Paradigms. Eur Urol. 2009 Jul;56(1):48–56.
Jhan JH, Yeh HC, Chang YH, Guu SJ, Wu WJ, Chou YH, et al. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study. J Diabetes Complications. 2018 Jul;32(7):688–92.
Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support Care Cancer. 2017 Jun 10;
Keogh JWL, MacLeod RD. Body Composition, Physical Fitness, Functional Performance, Quality of Life, and Fatigue Benefits of Exercise for Prostate Cancer Patients: A Systematic Review. J Pain Symptom Manage. 2012 Jan;43(1):96–110.
Kumar RJ. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol. 2005;7(Suppl 5):S37.
Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer (review). Cochrane Database Syst Rev. 2014;(6).
Larkin D, Lopez V, Aromataris E. Managing cancer-related fatigue in men with prostate cancer: A systematic review of non-pharmacological interventions. Int J Nurs Pract. 2014 Oct;20(5):549–60.
Lopez P, Newton RU, Taaffe DR, Singh F, Buffart LM, Spry N, et al. Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis. Prostate Cancer Prostatic Dis. 2022 Dec;25(4):615–26.
Luo YH, Yang YW, Wu CF, Wang C, Li WJ, Zhang HC. Fatigue prevalence in men treated for prostate cancer: A systematic review and meta-analysis. World J Clin Cases. 2021 Jul 26;9(21):5932–42.
Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2015 Sep 17;1–10.
Marzouk S, Naglie G, Tomlinson G, Duff Canning S, Breunis H, Timilshina N, et al. Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer. J Urol [Internet]. 2018 Mar 1 [cited 2018 Aug 10]; Available from: http://www.sciencedirect.com/science/article/pii/S0022534718393790
Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol [Internet]. 2015 Feb 17 [cited 2015 May 8]; Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.7510
Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015;7(6):378–87.
Myint ZW, Momo HD, Otto DE, Yan D, Wang P, Kolesar JM. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors. JAMA Netw Open. 2020 Nov 17;3(11):e2025826.
National Institute for Clinical Excellence. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. 2016.
National Institute for Health and Care Excellence. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. Technology appraisal guidance 387. 2016.
National Institute for Health and Care Excellence. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer. Technology Appraisal 660. 2020.
National Institute for Health and Care Excellence. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [Internet]. NICE; 2023 [cited 2023 Dec 5]. Available from: https://www.nice.org.uk/guidance/ta903
National Institute for Health and Care Excellence. Degarelix for treating advanced hormone-dependent prostate cancer. Technology appraisal guidance 404 [Internet]. 2016. Available from: https://www.nice.org.uk/guidance/TA404/chapter/1-Recommendations
National Institute for Health and Care Excellence. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. Technology appraisal guidance 377. 2016.
National Institute for Health and Care Excellence. Enzalutamide for treating hormone-sensitive metastatic prostate cancer [Internet]. 2021. Available from: https://www.nice.org.uk/guidance/ta712
National Institute for Health and Care Excellence. Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen. Technology appraisal guidance 316. 2014.
National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture. 2012.
National Institute for Health and Care Excellence. Overview | Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | Guidance | NICE [Internet]. NICE; 2021 [cited 2021 Nov 2]. Available from: https://www.nice.org.uk/guidance/ta740
National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management [Internet]. 2021 [cited 2022 Dec 19]. Available from: https://www.nice.org.uk/guidance/ng131
National Institute for Health and Clinical Excellence. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [Internet]. NICE; 2021 [cited 2023 Jan 23]. Available from: https://www.nice.org.uk/guidance/ta741/resources/apalutamide-with-androgen-deprivation-therapy-for-treating-hormonesensitive-metastatic-prostate-cancer-pdf-82611309932485
Nead KT, Boldbaatar N, Yang DD, Sinha S, Nguyen PL. Association of Androgen Deprivation Therapy and Thromboembolic Events: a Systematic Review and Meta-Analysis. Urology [Internet]. 2018 Jan [cited 2018 Jan 29]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0090429518300165
Nead KT, Sinha S, Nguyen PL. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017 Sep;20(3):259–64.
Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urol Oncol Semin Orig Investig. 2017 Nov 1;35(11):664.e1-664.e9.
Nguyen PL, Alibhai SMH, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. Eur Urol. 2015 May;67(5):825–36.
Prostate cancer - Treatment [Internet]. nhs.uk. 2021 [cited 2023 May 15]. Available from: https://www.nhs.uk/conditions/prostate-cancer/treatment/
Overkamp M, Houben LHP, Aussieker T, van Kranenburg JMX, Pinckaers PJM, Mikkelsen UR, et al. Resistance Exercise Counteracts the Impact of Androgen Deprivation Therapy on Muscle Characteristics in Cancer Patients. J Clin Endocrinol Metab. 2023 Oct 1;108(10):e907–15.
Owen PJ, Daly RM, Livingston PM, Fraser SF. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis. 2017 Jun;20(2):137–45.
Park KK, Lee SH, Chung BH. The Effects of Long‐Term Androgen Deprivation Therapy on Penile Length in Patients with Prostate Cancer: A Single‐Center, Prospective, Open‐Label, Observational Study. J Sex Med. 2011 Nov;8(11):3214–
Pettersson A, Johansson B, Persson C, Berglund A, Turesson I. Effects of a dietary intervention on acute gastrointestinal side effects and other aspects of health-related quality of life: A randomized controlled trial in prostate cancer patients undergoing radiotherapy. Radiother Oncol. 2012 Jun;103(3):333–40.
Qan’ir Y. Management of Androgen Deprivation Therapy–Associated Hot Flashes in Men With Prostate Cancer. Number 4 July 2019. 2019 Jul 1;46(4):E107–18.
Qazi SU, Altaf Z, Zafar M, Tariq MA, Khalid A, Kaleem A, et al. Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis. The Prostate. 2024;84(6):525–38.
Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N. Hormone and Radiotherapy versus Hormone or Radiotherapy Alone for Non-metastatic Prostate Cancer: A Systematic Review with Meta-analyses. Clin Oncol. 2014 Oct;26(10):e21–46.
Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE. Androgen deprivation therapy: past, present and future. BJU Int. 2012 Jun;109 Suppl 6:1–12.
Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M, et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer: Medicine (Baltimore). 2016 Jul;95(27):e3845.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166(4):465–71.
Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013;16(1):7–15.
Sountoulides P, Rountos T. Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: Prevention and Management. ISRN Urol [Internet]. 2013 Jul 25 [cited 2015 Nov 3];2013. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747499/
Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, et al. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol. 2018 Jun 1;199(6):1417–25.
Thorsen L, Courneya KS, Stevinson C, Fosså SD. A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer. 2008 Feb 15;16(9):987–97.
Tillisch K. Complementary and alternative medicine for functional gastrointestinal disorders. Gut. 2006 May 1;55(5):593–6.
Treanor CJ, Li J, Donnelly M. Cognitive impairment among prostate cancer patients: An overview of reviews. Eur J Cancer Care (Engl). 2017 Nov 1;26(6):e12642.
Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet. 2011 Dec;378(9809):2104–11.
Wedlake LJ, Shaw C, Whelan K, Andreyev HJN. Systematic review: the efficacy of nutritional interventions to counteract acute gastrointestinal toxicity during therapeutic pelvic radiotherapy. Aliment Pharmacol Ther. 2013 Jun;37(11):1046–56.
White ID, Wilson J, Aslet P, Baxter AB, Birtle A, Challacombe B, et al. Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer. Int J Clin Pract. 2015 Jan;69(1):106–23.
Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS. Risk of Urinary Incontinence Following Prostatectomy: The Role of Physical Activity and Obesity. J Urol. 2010 Feb;183(2):629–33.
Wu LM, Tanenbaum ML, Dijkers MPJM, Amidi A, Hall SJ, Penedo FJ, et al. Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study. Soc Sci Med. 2016 May 1;156:80–9.

List of reviewers

This publication has been reviewed for accuracy and updated by:

Joe Kearney, Macmillan Urology Oncology Clinical Nurse Specialist, Buckinghamshire Healthcare NHS Trust
Robert Jones, Professor of Clinical Cancer Research and Honorary Consultant in Medical Oncology, University of Glasgow and The Beatson West of Scotland Cancer Centre
our Health Information team
our Specialist Nurses
our volunteers.

Contents